Keryx Biopharmaceuticals, Inc. and Siegfried announced they had entered into a Master Manufacturing Services and Supply Agreement for Siegfried to perform certain manufacturing activities at its manufacturing facilities in Saint Vulbas, France and Pennsville, New Jersey as well as to manufacture and supply GMP-grade quantities of the proprietary active pharmaceutical ingredient for Keryx’s drug product, Auryxia.
The Agreement has an initial term ending on December 31, 2021 and will automatically renew after that for successive terms of one year each.
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange.
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
Keryx Biopharmaceuticals, Inc. is a US biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers.